Hormonal birth control can be associated with changes in sexual desire for some people, but it does not reliably lower—or raise—libido for everyone. Research, particularly on combined oral contraceptives, does not show one clear population-wide effect. A change after starting, stopping, or switching contraception deserves attention, but it may reflect the specific method, dryness or pain, mood, stress, sleep, other medicines, relationship context, or relief from unintended-pregnancy anxiety as well as hormones.
If the change is persistent, distressing, or affects comfort during sex, speak with a clinician or pharmacist before changing contraception. Do not stop, skip, remove, or switch a prescribed method on your own if avoiding pregnancy matters; pregnancy protection and any need for backup depend on the method and timing.
The short answer: hormonal birth control may affect libido, but not in one predictable direction
Libido means sexual desire or interest: the wish or inclination to engage in sexual activity. It is not a universal biological readout, and it can change over time for many reasons.
It is reasonable to notice that desire changed after a contraception change. Timing is useful information. But timing alone cannot establish a single cause. New relationship circumstances, life stress, a sleep change, postpartum recovery, pain, depression or anxiety, and medicines started around the same time may also contribute.
The most accurate answer to “does hormonal birth control affect libido?” is therefore two-part: average research findings do not support a uniform effect, while individual experiences can still be meaningful and worth discussing. A lack of a clear average effect does not mean that your experience is unimportant—or that hormones are necessarily the only explanation.
Libido is not the same as arousal, dryness, pain, orgasm, or satisfaction
“My libido is lower” can describe several different experiences. Naming the specific outcome helps make a clinical conversation more useful and avoids treating every sexual concern as a desire problem.
| Sexual outcome | How it may feel | Potential contraception-related pathway | Other common contributors | Useful discussion prompt |
|---|---|---|---|---|
| Desire or interest | Less wish to initiate or engage in sex | Possible hormone-related or mood-related change; effects vary | Stress, depression, anxiety, relationship strain, medicines | “When did my interest change, and what else changed then?” |
| Arousal | Harder to feel mentally or physically turned on | May overlap with side effects or hormonal pathways under study | Fatigue, worry, distraction, pain, expectations | “Is the main issue interest, arousal, or both?” |
| Vaginal dryness or lubrication | Less lubrication, friction, or irritation | Possible estrogen-related symptoms for some people | Postpartum or menopausal changes, medicines, insufficient arousal | “Do I have dryness even when I want sex?” |
| Pain or discomfort | Burning, soreness, pain with penetration, or pelvic discomfort | Dryness or bleeding changes may affect comfort indirectly | Pelvic conditions, infection, postpartum healing, menopause | “Where is the discomfort, and is there bleeding or pelvic pain?” |
| Orgasm or pleasure | Less pleasure or more difficulty reaching orgasm | May change alongside arousal or mood, but is a separate outcome | Stress, pain, communication, medication effects | “Has pleasure changed, orgasm changed, or both?” |
| Satisfaction or distress | Sex feels less satisfying or the change is upsetting | May be influenced indirectly by any side effect | Relationship context, expectations, frequency, health concerns | “How much is this affecting my wellbeing or relationship?” |
Evidence note: Direct comparisons across pills, patches, rings, implants, injections, progestin-only pills, and hormonal IUDs are limited and often observational. Current evidence does not support a reliable method ranking for sexual function.
What does the research say about the pill and sexual desire?
The strongest body of research concerns combined oral contraceptives, which contain an estrogen and a progestin. The Faculty of Sexual & Reproductive Healthcare guideline on combined hormonal contraception concludes that there is no clear evidence of a consistent association between combined pills containing at least 20 micrograms of ethinylestradiol and libido. It also emphasizes that desire is influenced by social, psychological, health, age, and medication factors.
Placebo-controlled trials give a more rigorous, though still limited, view. In a 2018 placebo-controlled trial of 202 participants (Lundin and colleagues), an estradiol/nomegestrol combined pill was associated with a small reduction in sexual-interest scores compared with placebo. Yet clinically relevant deterioration and overall sexual-function scores did not differ between groups after three cycles. In another three-month placebo-controlled trial of 340 participants (Zethraeus and colleagues, 2016) using levonorgestrel/ethinylestradiol, overall sexual function, satisfying sexual episodes, and personal distress were similar to placebo, even though desire, arousal, and pleasure domain scores were lower.
These studies matter because participants were randomly assigned and compared with placebo. However, each tested a particular pill for a short period. They cannot predict one person’s response or establish what will happen with every combined-pill formulation, much less every hormonal method.
An older systematic review of 36 studies of combined-pill users found that most participants reported no change or an increase in libido, while 15% reported a decrease. That figure is descriptive, not a personal probability: the studies were heterogeneous, used different measures, and were largely observational.
Do different hormonal methods affect sex drive differently?
Combined pills, patches, and rings are related because they are combined hormonal methods, but route, formulation, side effects, and personal experience are not interchangeable. Evidence about sexual outcomes is much less certain for progestin-only pills, implants, injections, and hormonal IUDs. Our article on progesterone and libido explains how natural progesterone and synthetic progestins differ.
A six-month observational analysis from the Contraceptive CHOICE Project (Boozalis and colleagues, 2016) found that users of depot medroxyprogesterone acetate injection, the vaginal ring, and the implant reported lack of sexual interest more often than copper-IUD users. After adjustment, hormonal-IUD, pill, and patch users did not differ from copper-IUD users. This finding is useful for identifying questions worth studying, but it does not prove that a method caused the reported difference. People choose methods for different reasons and may differ in health, relationships, baseline symptoms, and pregnancy concerns before beginning them.
Hormonal IUDs act mainly in the uterus but can still have systemic effects; that fact alone does not predict sexual effects. A 2023 systematic review of hormonal and copper IUD studies (Ogle and colleagues) found mostly neutral effects on sexual function, some evidence of less sexual pain with hormonal IUDs, and a need for more randomized trials. Likewise, choosing a copper IUD or another non-hormonal method is not automatically better for desire, comfort, or satisfaction.
Mechanism is not destiny
Method and formulation may influence biological measures and side effects. Those possible changes then interact with mood and sleep, pain or dryness, relationship context, other medicines, and confidence about pregnancy prevention. The result may differ across separate outcomes: desire, arousal, lubrication, comfort, pleasure, orgasm, satisfaction, and distress.
This framework is more useful than a hormone-only explanation. Combined pills often raise sex hormone-binding globulin (SHBG) and lower measured free testosterone. Ovulation suppression and estrogen-related symptoms are also among the biological pathways researchers study. But a biomarker change does not prove that desire will decline, identify the cause of a person’s symptoms, or show that hormone testing will provide an answer.
Indirect pathways may be just as important. Bleeding changes, headaches, acne, breast symptoms, or mood changes can alter how someone feels about sex. Conversely, a method may reduce menstrual pain or heavy bleeding, make cycles more predictable, or reduce anxiety about unintended pregnancy. For some people, that increased confidence may support a more positive sexual experience. None of these pathways is guaranteed.
Physiology is one part of sexual experience, not a standalone explanation. Symptoms alone usually cannot reveal the relative contribution of hormones, comfort, mood, medication effects, relationship context, and pregnancy confidence.
Why the evidence is difficult to interpret
“Mixed evidence” does not mean researchers know nothing. It means the studies do not support a simple, universal claim. Sexual-function research faces several challenges:
- Studies use different definitions and questionnaires for desire, arousal, lubrication, pleasure, orgasm, satisfaction, and distress.
- Many studies are short and examine a specific formulation, limiting generalization.
- Observational comparisons cannot fully remove self-selection: people choose contraception for different medical, practical, and personal reasons.
- People who experience unwanted effects may discontinue a method, which can shape who remains in later analyses.
- Relationship changes, stress, health conditions, pregnancy concerns, and changes in other medicines can occur during follow-up.
An evidence ladder can help: placebo-controlled trials are stronger for estimating effects of the formulation tested, but are often short-term; observational comparisons can show patterns but cannot establish cause; biomarker studies can clarify mechanisms under study but cannot prove lived sexual outcomes.
What to do if birth control seems to be lowering your libido
You do not need to wait for a fixed period before raising a concern. If it matters to you, it is appropriate to discuss it.
- Track the timing and the specific change. Note when it began relative to starting, stopping, or changing a method. Record whether the issue is desire, arousal, dryness, pain, pleasure, orgasm, satisfaction, or distress.
- Review the wider context. Consider sleep, stress, mood, relationship changes, postpartum or breastfeeding status, perimenopausal or menopausal changes, pain, and new medicines. The NHS guidance on loss of libido lists hormonal contraception among many potential contributors, including health conditions and medication effects.
- Bring focused questions to a clinician or pharmacist. Ask whether the timing and symptoms warrant a review of your method, other medicines, mood, pain, or relevant health history; explain your pregnancy-prevention priorities and consider how to communicate sexual needs with your partner.
- Protect against unintended pregnancy during any change. Starting, changing, or stopping methods can alter protection. Method-specific transition and backup needs vary, so consult a clinician, pharmacist, or the CDC’s method-specific guidance rather than guessing.
Most contraceptive methods do not protect against sexually transmitted infections, including HIV. Condoms can be used alongside another contraceptive method for STI/HIV protection.
When to speak with a clinician sooner
Seek clinical review sooner if a change in desire or sexual comfort is persistent, distressing, or affecting your wellbeing or relationship. It is also important to raise new vaginal dryness, pain during sex, unusual bleeding concerns, pelvic symptoms, major mood changes, or worries about a medicine’s side effects.
Postpartum and breastfeeding changes, perimenopause or menopause, anxiety or depression, and health conditions such as thyroid disease can overlap with sexual concerns. A clinician can help consider these possibilities without assuming contraception is the sole cause. If you feel unsafe or have thoughts of self-harm, seek urgent mental-health support in your area.
Bottom line: a change is worth taking seriously, even when the cause is unclear
Hormonal contraception may contribute to changes in sexual experience for some people, but no universal libido effect has been shown across methods or users. The most useful next step is to name what changed, consider the full context, and seek method-specific guidance before altering contraception. Your experience does not need to fit a simple hormone story to deserve care. Related articles are collected in our Anatomy & Hormones topic page.
Further reading
In Understanding Female Pleasure: Science and Society, Chapter 2, Anatomy & Physiology, explores the body’s role in sexual wellbeing in more depth.
Disclosure: this book is promoted by Women, Science & Society. It is optional background reading, not a medical resource, and not a substitute for the sources cited above or for advice from a clinician.
